Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Patrick J. McEnany net worth and biography

Patrick McEnany Biography and Net Worth

CEO of Catalyst Pharmaceuticals

Patrick J. McEnany has been Chief Executive Officer and a director of Catalyst since its formation in January 2002. In 2006 he became Chairman, President and Chief Executive Officer. From 1991 to April of 1997, Mr. McEnany was Chairman and Chief Executive Officer of Royce Laboratories, Inc. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as President of the wholly-owned Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals, Inc. From 1993 through 1997, he also served as Vice Chairman and Director of the National Association of Pharmaceutical Manufacturers. He currently serves on the Board of Directors for the Jackson Memorial Hospital Foundation.

What is Patrick J. McEnany's net worth?: The estimated net worth of Patrick J. McEnany is at least $59.69 million as of May 15th, 2023. Mr. McEnany owns 3,945,436 shares of Catalyst Pharmaceuticals stock worth more than $59,694,447 as of April 20th. This net worth evaluation does not reflect any other investments that Mr. McEnany may own. Additionally, Mr. McEnany receives a salary of $1,200,000.00 as CEO at Catalyst Pharmaceuticals. Learn More about Patrick J. McEnany's net worth.
How old is Patrick J. McEnany?: Mr. McEnany is currently 77 years old. There are 6 older executives and no younger executives at Catalyst Pharmaceuticals. Learn More on Patrick J. McEnany's age.
What is Patrick J. McEnany's salary?: As the CEO of Catalyst Pharmaceuticals, Inc., Mr. McEnany earns $1,200,000.00 per year. Learn More on Patrick J. McEnany's salary.
How do I contact Patrick J. McEnany?: The corporate mailing address for Mr. McEnany and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Patrick J. McEnany's contact information.
Has Patrick J. McEnany been buying or selling shares of Catalyst Pharmaceuticals?: Patrick J. McEnany has not been actively trading shares of Catalyst Pharmaceuticals during the past quarter. Most recently, Patrick J. Mcenany sold 26,151 shares of the business's stock in a transaction on Monday, May 15th. The shares were sold at an average price of $13.23, for a transaction totalling $345,977.73. Following the completion of the sale, the chief executive officer now directly owns 3,945,436 shares of the company's stock, valued at $52,198,118.28. Learn More on Patrick J. McEnany's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Alicia Grande (CFO), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), and Steven Miller (COO & Chief Scientific Officer ). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 266,151 shares worth more than $3,781,377.73. The most recent insider tranaction occured on April, 8th when Director David S Tierney sold 25,000 shares worth more than $392,000.00. Insiders at Catalyst Pharmaceuticals own 12.1% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Patrick J. McEnany Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2023	Sell	26,151	$13.23	$345,977.73	3,945,436
11/21/2022	Sell	150,000	$15.33	$2,299,500.00	3,902,606
11/18/2022	Sell	350,000	$15.62	$5,467,000.00	3,902,606
9/13/2022	Sell	80,765	$15.33	$1,238,127.45	4,849,452
8/23/2021	Sell	82,617	$5.62	$464,307.54	4,928,304
8/20/2021	Sell	54,161	$5.52	$298,968.72
9/30/2020	Buy	15,000	$2.97	$44,550.00	4,787,693
10/3/2019	Buy	10,000	$4.89	$48,900.00	4,772,693
6/11/2019	Buy	25,000	$3.23	$80,750.00	4,762,693
12/19/2018	Buy	20,000	$2.24	$44,800.00	4,737,693
4/3/2018	Buy	20,000	$2.29	$45,800.00
9/5/2017	Buy	20,000	$2.58	$51,600.00	4,471,026
6/14/2016	Buy	105,300	$0.65	$68,445.00	4,393,109
4/26/2016	Buy	50,000	$0.65	$32,500.00	4,287,809
12/28/2015	Buy	25,000	$2.39	$59,750.00	4,237,809
10/1/2015	Buy	10,000	$2.81	$28,100.00	4,137,262
4/27/2015	Buy	5,000	$3.79	$18,950.00
1/8/2015	Buy	50,000	$2.80	$140,000.00
10/21/2013	Buy	50,000	$1.59	$79,500.00
2/19/2013	Buy	50,000	$0.46	$23,000.00
12/17/2012	Buy	100,000	$0.45	$45,000.00
11/15/2012	Buy	100,000	$0.42	$42,000.00

Patrick J. McEnany Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $15.13

$15.03

$15.80

50 Day Range

MA: $15.41

$13.18

$17.01

2 Week Range

Now: $15.13

$11.09

$17.76

Volume

7,421,393 shs

Average Volume

1,502,695 shs

Market Capitalization

$1.79 billion

P/E Ratio

24.80

Dividend Yield

N/A

Beta

0.89

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

Patrick McEnany Biography and Net Worth

What is Patrick J. McEnany's net worth?

How old is Patrick J. McEnany?

What is Patrick J. McEnany's salary?

How do I contact Patrick J. McEnany?

Has Patrick J. McEnany been buying or selling shares of Catalyst Pharmaceuticals?

Who are Catalyst Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Catalyst Pharmaceuticals?